Inventor · disambiguated record
Jason Marc Foulks
Also filed as: FOULKS JASON MARC
7 granted patents·11 pending applications·28 citations·filing 2013–2024
80Inventor score
Files withSUMITOMO PHARMA ONCOLOGY INC9TOLERO PHARMACEUTICALS INC4SUMITOMO DAINIPPON PHARMA ONCOLOGY INC3MAYO FOUND MEDICAL EDUCATION & RES1SUMITOMO PHARMA AMERICA INC1
Top patents by PatentIndex Score
18 records- 0195US9394257B2PKM2 modulators and methods for their useTOLERO PHARMACEUTICALS INC·Filed 2013·Granted Jul 19, 2016·22 cites·52 claims
- 0282US10766865B2PKM2 modulators and methods for their useTOLERO PHARMACEUTICALS INC·Filed 2019·Granted Sep 8, 2020·1 cites·17 claims
- 0382US10472328B2PKM2 modulators and methods for their useTOLERO PHARMACEUTICALS INC·Filed 2018·Granted Nov 12, 2019·2 cites·20 claims
- 0482US2024173319A1Solid dose pharmaceutical compositionSUMITOMO PHARMA ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 0580US2023390288A1Solid dose pharmaceutical compositionSUMITOMO PHARMA ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 0679US10207996B2PKM2 modulators and methods for their useTOLERO PHARMACEUTICALS INC·Filed 2016·Granted Feb 19, 2019·2 cites·37 claims
- 0777US2023181586A1Solid dose pharmaceutical compositionSUMITOMO PHARMA ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 0876US11040038B2Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the sameSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2019·Granted Jun 22, 2021·1 cites·11 claims
- 0972US2025082634A1Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancerSUMITOMO PHARMA AMERICA INC·Filed 2024·Application pending·0 cites
- 1071US2021002233A1Pkm2 modulators and methods for their useSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 1168US2023000864A1Solid dose pharmaceutical compositionSUMITOMO PHARMA ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 1268US2023165857A1Axl kinase inhibitors and use of the sameSUMITOMO PHARMA ONCOLOGY INC·Filed 2022·Application pending·0 cites
- 1362US11400091B2AXL kinase inhibitors and use of the sameSUMITOMO PHARMA ONCOLOGY INC·Filed 2020·Granted Aug 2, 2022·0 cites·36 claims
- 1461US2021113562A1Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancerSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2019·Application pending·0 cites
- 1561US2024360135A1Imidazo[1,2-b]pyridazinyl compounds and uses thereofSUMITOMO PHARMA ONCOLOGY INC·Filed 2022·Application pending·0 cites
- 1658US11712433B2Compositions comprising PKM2 modulators and methods of treatment using the sameSUMITOMO PHARMA ONCOLOGY INC·Filed 2020·Granted Aug 1, 2023·0 cites·19 claims
- 1757US2024091226A1Forms and Formulations Of A Tyrosine Kinase Non-Receptor 1 (TNK1) InhibitorSUMITOMO PHARMA ONCOLOGY INC·Filed 2022·Application pending·0 cites
- 1849US2021145830A1Materials and methods for treating cancerMAYO FOUND MEDICAL EDUCATION & RES·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jason Marc Foulks files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →